Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Fish Oil Lipid Emulsion in Pediatric HCT
NCT02512718Phase 1Completed
- Start
- Jun 2016
- Primary completion
- May 2023
- Modality
- Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of eicosapentaenoic acid + docosahexaenoic acid in hematologic malignancy and myelodysplastic syndromes (MDS) (2 arms). Primary endpoint: Incidence of adverse events at 100 days. Started Jun 2016; status: completed.
02
Drugs
eicosapentaenoic acid + docosahexaenoic acid
03
Conditions
hematologic malignancymyelodysplastic syndromes (MDS)
Beyond the preview
Go deeper on NCT02512718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02512718.